1. Home
  2. VAL vs PTCT Comparison

VAL vs PTCT Comparison

Compare VAL & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$75.40

Market Cap

5.4B

Sector

Energy

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$83.64

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
PTCT
Founded
1975
1998
Country
Bermuda
United States
Employees
5070
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
VAL
PTCT
Price
$75.40
$83.64
Analyst Decision
Hold
Buy
Analyst Count
5
17
Target Price
$64.00
$80.65
AVG Volume (30 Days)
846.9K
1.9M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
264.48
EPS
N/A
N/A
Revenue
N/A
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.76
$17.70
P/E Ratio
$16.22
N/A
Revenue Growth
N/A
36.19
52 Week Low
$41.23
$43.18
52 Week High
$114.12
$87.50

Technical Indicators

Market Signals
Indicator
VAL
PTCT
Relative Strength Index (RSI) 30.68 68.32
Support Level $47.57 $73.41
Resistance Level $104.05 $87.50
Average True Range (ATR) 3.04 3.06
MACD -1.03 1.01
Stochastic Oscillator 6.09 79.99

Price Performance

Historical Comparison
VAL
PTCT

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: